Evolent Health (EVH) Oppenheimer 36th Annual Healthcare MedTech & Services Conference summary

Business update and implementation progress

• Smooth implementations of Aetna and on-track Highmark launch are key revenue drivers for the year.

• Early exchange membership numbers are being monitored, with more clarity expected in coming months.

• No significant changes since the last update; business is progressing as planned.

Financial guidance and seasonality

• Guidance is conservative due to new client risk revenue and associated reserving practices.

• Fourth quarter expected to benefit from reduced reserving and contractual reimbursement adjustments.

• Sequential EBITDA improvement projected in Q3 and Q4, with Q4 run rate around $150 million.

Cost trends and provider dynamics

• Cardio cost trends are slightly lower than expected; oncology trends remain stable.

• No significant provider pushback on authorizations; clinical approach is well received.